The country's first large-scale chest tumor precision medical research center was established.

(Health Times online reporter Wen Wei)
. In order to further strengthen the development process of precision diagnosis and treatment of chest tumors in China and promote the transformation of cutting-edge research and clinical research in the field of chest tumors, on September 6th, the Shanghai Chest - and Rui Gene Precision Medical Research Center was established at Shanghai Chest Hospital. This is China's first large-scale chest tumor precision medical research center, with a view to exploring a path of tumor precision medicine, so that tumor patients enjoy personalized precision medical services as soon as possible.
differential treatment of cancer based on genetic testing has become a trend
chest tumor, especially lung cancer, has become the most common tumor in the world. According to the latest cancer statistics released by the National Cancer Center in January 2019, lung cancer ranks first among the most malignant tumors in China, with about 787,000 new cases in 2015 and about 631,000 deaths due to lung cancer.
at present, the differential treatment of individual tumorbased on individual genetic testing has become an important trend. Tumor is a complex multi-gene disease, because of the individual differences of patients, traditional drug therapy will produce a great difference in the effect of drug use. Precision medicine is based on the molecular characteristics of tumor patients, and genetic testing is the core of precision medicine. Genetic testing can help doctors select potential targeted drugs based on genetic analysis.
as the benchmark hospital of chest tumor clinical practice in Shanghai Chest Hospital, and the field of tumor genetic testing representative enterprises and Ruigene joint, give full play to the advantages of the cooperation in clinical resources and genetic testing, through the effective integration of clinical information and genetic information, the effective integration of chest tumor precision treatment clinical research and cutting-edge scientific research, and scientific research to drive clinical transformation and technical output. The result is a "tailored" and precise treatment for more patients with chest tumors.Zhu Qigao, Deputy Director of the Shanghai Science and Technology Commission of
, Guo Yongxuan, Deputy Director of Shanghai Shenkang Hospital Development Center, Pan Changqing, President of Shanghai Chest Hospital, Yu Yongchun, Vice President, Dr. Zhou Daixing, Director of Ruigene/Berry Gene, and Zhou Wei, General Manager of Ruigen.Pan Changqing, president of Shanghai Chest Hospital, ,
", "Through this cooperation, on the one hand, to improve the clinical research capacity of the chest hospital, in the technical support of Ruigene, so that the thoracic hospital has a domestic and comprehensive grasp of the various generations of gene analysis and testing technology of clinical institutions, and further establish the chest hospital in the industry-wide discipline advantages." "Director Pan Changqing of Shanghai Chest Hospital introduced."
for the signing of the cooperation, and Ruigen General Manager Zhou Wei said, and Ruigen hope to combine the technology and experience in the field of tumor genetic detection, combined with advanced clinical research and rich clinical resources of Shanghai Chest Hospital, through big data-based letter analysis to explore the relationship between genetic variation and efficacy, the law of genetic variation in the course of treatment and the relationship with efficacy, to provide new ideas and support ingenuity to modify clinical treatment guidelines, in the chest tumor diagnosis, early diagnosis, early diagnosis, early diagnosis.
the cooperation between hospitals and enterprises, to build a first-class cancer precision research center
precision medicine throughout the diagnosis, testing, treatment of cancer patients and other links, how to help clinical experts to provide patients with accurate diagnosis and treatment solutions?
as a large-scale chest tumor precision medical research center jointly built by domestic hospitals and enterprises, at the beginning of its establishment, the research center will establish a high-level quality control system with international standards and institutional operation system, so that the center has information integrity, traceability, easy to call, expand flexible sample library, database and gene sequencing center. Realize the multi-dimensional and comprehensive approach from solid samples to digital samples, from DNA molecular information to clinical phenotype information, from individual cases to large data analysis of populationdata, and ultimately help clinicians provide accurate diagnosis and treatment for patients with chest tumors.
high-quality clinical data and high-quality genetic data are necessary for high-quality research results and a necessary basis for promoting peer exchanges at home and abroad. The establishment of the Shanghai Chest - and Ruigene Precision Medicine Research Center is to build a first-class level of the cancer precision research center with hardware and software.Yu Yongchun, vice president of Shanghai Chest Hospital, , introduced the construction plan of "two libraries and one center"
The Shanghai Chest Hospital, namely, the construction of an automated, modular "biological sample bank";The
Center will initially invest 20,000 clinical testing resources, focusing on the accompanying diagnosis of
drug clinical trial research, tumor diagnosis is the study of individualized drug use, tumor marker prognosis research, tumor susceptibility assessment, and early prevention screening
of tumors and major diseases. The overall study was initially completed in 2 to 3 years.
in addition, the Precision Research Center will establish a molecular genetic testing laboratory in line with national standards, and will participate in the National Health and Safety Commission Pre-Inspection Center high-throughput sequencing room quality evaluation and application for ISO, CAP and other international certification. The design of the centre has been approved by the competent authorities and will be completed by November this year for construction and trial operation, and is expected to be fully operational by the end of the year.
.